The analysis represents an effort to use bioinformatics to find potential new therapeutic targets for myasthenia gravis (MG). A new genetic analysis of patients with thymoma-associated myasthenia ...

An additional secondary analysis found that semaglutide 2.4 mg, when compared to placebo, showed improvements in both liver injury and in liver scarring across various ages, genders, races, and ...

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated ...

The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an ...

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Results for 8-week 48 mg Cohort ...

Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous ...

Overall, 3,620 US patients were identified: 2,870 treated with goserelin 3.6 mg once every 4 weeks, 410 treated with 10.8 mg once every 12 weeks, and 340 switched from 3.6 mg once every 4 weeks to ...